Search Within

Margaret Kathleen Callahan

Formats
  1. Journal Article (104)
  2. Meeting Abstract (83)
  3. Editorial (4)
  4. Book Section (2)
  5. Research Letter (2)
  6. Guidelines (1)
  7. Review (1)
Groups
  1. Department of Medicine (197)
  2. Melanoma and Immunotherapeutics Service (197)
  3. Solid Tumor Oncology Division (197)
  4. GSK Faculty (123)
  5. Melanoma Disease Management Team (107)
  6. Hematologic Malignancies, Division of (76)

More Groups

People
  1. Jedd Wolchok (113)
  2. Michael Postow (95)
  3. Paul Chapman (49)
  4. Alexander Shoushtari (45)
  5. Katherine Panageas (38)
  6. Parisa Momtaz (29)

More People

Years
  1. 2025 (3)
  2. 2024 (6)
  3. 2023 (9)
  4. 2022 (13)
  5. 2021 (11)
  6. 2020 (19)

More Years

Publications
  1. Journal of Clinical Oncology (60)
  2. Journal for ImmunoTherapy of Cancer (17)
  3. Science Translational Medicine (10)
  4. Annals of Oncology (7)
  5. Clinical Cancer Research (7)
  6. New England Journal of Medicine (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (64)
  2. Biomed Central Ltd (17)
  3. Elsevier Inc. (17)
  4. American Association for Cancer Research (15)
  5. Oxford University Press (15)
  6. Nature Publishing Group (11)

More Publishers

Results (197)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
    Journal Article

    Rosner, S.; Kwong, E.; Shoushtari, A. N.; Friedman, C. F.; Betof, A. S.; Brady, M. S.; Coit, D. G.; Callahan, M. K.; Wolchok, J. D.; Chapman, P. B.; more...
    Cancer Medicine (2018)

    Fulltext@MSK | Save
  • Nivolumab plus ipilimumab in patients with advanced melanoma: Updated survival, response, and safety data in a phase I dose-escalation study
    Journal Article

    Callahan, M. K.; Kluger, H.; Postow, M. A.; Segal, N. H.; Lesokhin, A.; Atkins, M. B.; Kirkwood, J. M.; Krishnan, S.; Bhore, R.; Horak, C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma
    Journal Article

    Shoushtari, A. N.; Friedman, C. F.; Navid-Azarbaijani, P.; Postow, M. A.; Callahan, M. K.; Momtaz, P.; Panageas, K. S.; Wolchok, J. D.; Chapman, P. B.
    JAMA Oncology (2018)

    Fulltext@MSK | Save
  • OncoKB: A precision oncology knowledge base
    Journal Article

    Chakravarty, D.; Gao, J.; Phillips, S.; Kundra, R.; Zhang, H.; Wang, J.; Rudolph, J. E.; Yaeger, R.; Soumerai, T.; Nissan, M. H.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients
    Meeting Abstract

    Sanborn, R. E.; Pishvaian, M. J.; Kluger, H. M.; Callahan, M. K.; Weise, A. M.; Lutzky, J.; Yellin, M. J.; Rawls, T.; Vitale, L.; Halim, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Clinical benefit and toxicity of nivolumab plus ipilimumab in patients with advanced melanoma previously treated with checkpoint blockade inhibitors
    Meeting Abstract

    Friedman, C. F.; Wolchok, J. D.; Postow, M. A.; Shoushtari, A. N.; Callahan, M. K.; Momtaz, P.; Chapman, P. B.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs observed pharmacokinetics (PK) in ICONIC
    Meeting Abstract

    Burris, H. A.; Callahan, M. K.; Tolcher, A. W.; Kummar, S.; Falchook, G. S.; Pachynski, R. K.; Tykodi, S. S.; Gibney, G. T.; Seiwert, T. Y.; Gainor, J. F.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Initial efficacy of anti-lymphocyte activation gene-3 (anti-LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti-PD-1/PD-L1 therapy
    Meeting Abstract

    Ascierto, P. A.; Melero, I.; Bhatia, S.; Bono, P.; Sanborn, R. E.; Lipson, E. J.; Callahan, M. K.; Gajewski, T.; Gomez-Roca, C. A.; Hodi, F. S.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Neurotoxicity in patients with metastatic solid tumors treated with immune checkpoint inhibitors: A single institution retrospective analysis
    Meeting Abstract

    Santomasso, B.; Malani, R.; Haggiagi, A.; Holder, J.; Shames, Y.; Briggs, S.; Callahan, M.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • The development of neurologic immune related adverse events (irAEs) in patients with metastatic solid tumors treated with immune checkpoint inhibitors: A single institution retrospective analysis
    Meeting Abstract

    Malani, R.; Haggiagi, A.; Holder, J.; Shames, Y.; Briggs, S.; Santomasso, B.; Callahan, M.
    Neuro-Oncology (2017)

    Fulltext@MSK | Save